Gaurav Munj 2022-03-04T06:42:16+00:00 Press Releases Site - Investor Relations Nav Overview Press Releases Events and Presentations Financial Filings Stock Information Corporate Governance Contact Upcoming and Recent Events Corporate Presentation SEC Filings Stock Quote & Chart Governance Documents Committees Year None2022 November 9, 2022 Biohaven Ltd. Reports Third Quarter 2022 Financial Results and Reports Recent Business Developments October 25, 2022 Biohaven Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares October 25, 2022 Biohaven Advances Development of the MoDE Platform Technology Licensed From Yale University October 20, 2022 Biohaven Announces Pricing of Public Offering of Common Shares October 18, 2022 Biohaven Announces Launch of Public Offering of Common Shares October 4, 2022 Biohaven Sets New Course with $258 Million in Cash, a Proven Team and Deep Pipeline to Continue its Journey to Advance Science for Patients BIOHAVEN (BHVN) Volume Market Cap 52 Week High 52 Week Low Data Provided by Refinitiv. Minimum 15 minutes delayed.
Year None2022 November 9, 2022 Biohaven Ltd. Reports Third Quarter 2022 Financial Results and Reports Recent Business Developments October 25, 2022 Biohaven Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares October 25, 2022 Biohaven Advances Development of the MoDE Platform Technology Licensed From Yale University October 20, 2022 Biohaven Announces Pricing of Public Offering of Common Shares October 18, 2022 Biohaven Announces Launch of Public Offering of Common Shares October 4, 2022 Biohaven Sets New Course with $258 Million in Cash, a Proven Team and Deep Pipeline to Continue its Journey to Advance Science for Patients
November 9, 2022 Biohaven Ltd. Reports Third Quarter 2022 Financial Results and Reports Recent Business Developments
October 25, 2022 Biohaven Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
October 25, 2022 Biohaven Advances Development of the MoDE Platform Technology Licensed From Yale University
October 4, 2022 Biohaven Sets New Course with $258 Million in Cash, a Proven Team and Deep Pipeline to Continue its Journey to Advance Science for Patients
